Fatigue News and Research

RSS

Hemispherx announces publication of Ampligen Phase III data in Journal of Applied Research

Hemispherx Biopharma, Inc., announced the publication of a peer-reviewed article providing new data on Ampligen [rintatolimod; poly(I)·poly(C12,U)], an experimental therapeutic in Phase III clinical testing, in the current issue of The Journal of Applied Research.

23 Nov 2010

New study links high prevalence of insomnia and poor quality of life in software engineers

Insomnia is bad news for software engineers' quality of life and deserves greater recognition and attention, according to new research by Sara Sarrafi Zadeh and Khyrunnisa Begum from the University of Mysore in India. Their work shows that poor sleep has a bearing on quality of life - affecting physical and mental health in particular - in this group with high levels of job-related stress. Their paper is published online in Springer's journal Applied Research in Quality of Life.

22 Nov 2010

Simple strategies to cope with holiday stress

Dr. Richard Blonna, author, life coach, and stress management expert, offers five simple strategies for managing holiday stress. His approach to managing the worry and anxiety associated with holiday stress is adapted from his new book, Stress Less, Live More; How Acceptance and Commitment Therapy Can Help You Live a Busy Yet Balanced Life.

20 Nov 2010

Vascular Disease Foundation urges diabetic patients to be alert about P.A.D. signs

P.A.D. occurs when arteries in the legs become narrowed or clogged with fatty deposits, reducing blood flow to the legs. This can result in leg muscle pain when walking, disability, amputation, and poor quality of life. Blocked arteries found in people with P.A.D. can be a red flag that other arteries, including those in the heart and brain, may also be blocked - increasing the risk of a heart attack or stroke.

20 Nov 2010

Acceleron presents ACE-041 interim results for advanced cancer at EORTC-NCI-AACR Symposium

Acceleron Pharma, Inc., a biopharmaceutical company developing novel protein therapeutics that regulate the growth and development of tissues and cells, including muscle, bone, red blood cells, and vasculature, today announced the presentation of interim results from the first-in-human clinical study of ACE-041 in patients with advanced cancer at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Berlin, Germany.

20 Nov 2010

ACE-041 drug may provide new option to treat cancer

Researchers have found that a newly developed drug, which is aimed at a particular receptor involved in the development of blood vessels that sustain tumour growth, is active in patients with advanced cancers and, in some cases, has halted the progress of the disease. The drug, ACE-041, targets a different molecular pathway to other anti-angiogenesis drugs and may provide a new option to treat cancer.

19 Nov 2010

International businessman donates $50,000 for SCCO cancer study

International businessman and philanthropist Foster Friess has donated $50,000 to help launch a study of small cell carcinoma of the ovary (SCCO) by the Translational Genomics Research Institute (TGen) and the Van Andel Research Institute (VARI).

19 Nov 2010

AVEO announces results from tivozanib Phase 1b clinical trial for advanced gastrointestinal cancers

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced results from a Phase 1b clinical trial evaluating the company's lead product candidate, tivozanib, a highly potent and selective inhibitor of VEGF receptors 1, 2, and 3, in combination with FOLFOX6, a standard chemotherapy regimen, in patients with advanced gastrointestinal (GI) cancers.

19 Nov 2010

Aeterna presents data on AEZS-108 Phase 2 study for endometrial cancer at EORTC-NCI-AACR Symposium

Aeterna Zentaris Inc., earlier today, presented Phase 2 positive efficacy and safety data for its compound, AEZS-108, in advanced endometrial cancer.

18 Nov 2010

Medivir AB reports positive interim data on Phase 2b ASPIRE study for hepatitis C

Medivir AB, the emerging research-based specialty pharmaceutical company focused on infectious diseases announces today positive top-line 24-week interim data from the Phase 2b ASPIRE (C206) study of TMC435 in treatment-experienced hepatitis C patients.

18 Nov 2010

MK-4827 drug candidate shows promising anti-tumour activity in first human trial

A new drug that targets proteins responsible for helping cancer cells to repair damage to their DNA has shown promising anti-tumour activity in its first trial in humans.

18 Nov 2010

Exelixis reports interim data of XL184 for metastatic castration-resistant prostate cancer

Exelixis, Inc. today reported interim data from the cohort of patients with metastatic castration-resistant prostate cancer (CRPC) treated with XL184 in an ongoing phase 2 adaptive randomized discontinuation trial (RDT).

18 Nov 2010

Exelixis reports interim data from phase 2 RDT trial for epithelial ovarian cancer

Exelixis, Inc. today reported interim data from the cohort of patients with advanced epithelial ovarian cancer, primary peritoneal, or fallopian tube carcinoma treated with XL184 in an ongoing phase 2 adaptive randomized discontinuation trial (RDT).

18 Nov 2010

Survey on palliative care for patients with dementia

A new national survey conducted by researchers from Indiana University and the Regenstrief Institute has found that while palliative care may be available for those with dementia, there are significant barriers to providing or receiving services to relieve the pain, eating difficulties and other symptoms associated with dementia.

17 Nov 2010

Study finds significant variability in CPR quality between day and night

CPR quality is worse during in-hospital cardiac arrests occurring overnight than those that happen during the day, according to a new University of Pennsylvania School of Medicine study that will be presented at the American Heart Association's annual Scientific Sessions on November 14.

16 Nov 2010

FDA approves Halaven therapy for metastatic late-stage breast cancer

The U.S. Food and Drug Administration today approved Halaven (eribulin mesylate) to treat patients with metastatic breast cancer who have received at least two prior chemotherapy regimens for late-stage disease.

16 Nov 2010

RBC boosting drugs may undermine breast cancer treatment with Herceptin

Red-blood-cell-boosting drugs used to treat anemia may undermine breast cancer treatment with Herceptin, a targeted therapy that blocks the cancer-promoting HER2 protein, researchers from The University of Texas MD Anderson Cancer Center report in the Nov. 16 edition of Cancer Cell.

16 Nov 2010

Findings reveal potential cause of lower survival from nighttime in-hospital cardiac arrest

15 Nov 2010

Young father receives life-saving intervention prior heart transplant surgery

James "Jimmy" Armstrong hadn't missed a "Mac" in 28 years. At 44, he's one of the youngest "goats" in the Chicago Yacht Club. Sailors receive the designation of "goat" once they've completed 20 or more "Macs", the 333-mile boat race from Chicago to Mackinac, Mich. Armstrong has sailed the race every year since he was 16. But, he wasn't among the sailors this past July. Instead, he was in intensive care awaiting heart transplant following a harrowing experience spurred by severe case of myocarditis-a little-known condition causing inflammation of the heart muscle.

15 Nov 2010

Clinical trial results of Threshold's TH-302 hypoxia-activated prodrug presented at 16th CTOS annual meeting

Threshold Pharmaceuticals, Inc. today announced clinical trial results related to Threshold's clinical stage hypoxia-activated prodrug, TH-302. The results were presented at the 16th Annual Connective Tissue Oncology Society (CTOS) Meeting taking place in Paris, France from November 11 to 13, 2010.

12 Nov 2010

Fatigue News and Research

Hemispherx announces publication of Ampligen Phase III data in Journal of Applied Research

New study links high prevalence of insomnia and poor quality of life in software engineers

Simple strategies to cope with holiday stress

Vascular Disease Foundation urges diabetic patients to be alert about P.A.D. signs

Acceleron presents ACE-041 interim results for advanced cancer at EORTC-NCI-AACR Symposium

ACE-041 drug may provide new option to treat cancer

International businessman donates $50,000 for SCCO cancer study

AVEO announces results from tivozanib Phase 1b clinical trial for advanced gastrointestinal cancers

Aeterna presents data on AEZS-108 Phase 2 study for endometrial cancer at EORTC-NCI-AACR Symposium

Medivir AB reports positive interim data on Phase 2b ASPIRE study for hepatitis C

MK-4827 drug candidate shows promising anti-tumour activity in first human trial

Exelixis reports interim data of XL184 for metastatic castration-resistant prostate cancer

Exelixis reports interim data from phase 2 RDT trial for epithelial ovarian cancer

Survey on palliative care for patients with dementia

Study finds significant variability in CPR quality between day and night

FDA approves Halaven therapy for metastatic late-stage breast cancer

RBC boosting drugs may undermine breast cancer treatment with Herceptin

Findings reveal potential cause of lower survival from nighttime in-hospital cardiac arrest

Young father receives life-saving intervention prior heart transplant surgery

Clinical trial results of Threshold's TH-302 hypoxia-activated prodrug presented at 16th CTOS annual meeting

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News